(Q35041705)

6 August 2017

1 reference

title

Prospects for immunotherapy of malignant disease (English)

1 reference

6 August 2017

1 reference

E C Morris

1

1 reference

PubMed ID

12519379

6 August 2017

G M Bendle

series ordinal

2

1 reference

PubMed ID

12519379

6 August 2017

H J Stauss

series ordinal

3

1 reference

6 August 2017

1 January 2003

1 reference

Clinical and Experimental Immunology

6 August 2017

1 reference

6 August 2017

131

1 reference

6 August 2017

1

1 reference

6 August 2017

1-7

1 reference

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Design and evaluation of antigen-specific vaccination strategies against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Clinical cancer vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Response of naïve and memory CD8+ T cells to antigen stimulation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

The enemy within: keeping self-reactive T cells at bay in the periphery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Ontogeny of T cell tolerance to peripherally expressed antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Cellular therapy: donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Changing T cell specificity by retroviral T cell receptor display

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Circumventing T-cell tolerance to tumour antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Selective loss of beta 2-microglobulin mRNA in human colon carcinoma

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction.

25 October 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1808603

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

9 December 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

In vivo manipulation of dendritic cells to induce therapeutic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2249.2003.02055.X

Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model

21 January 2018

1 reference

12 December 2020

Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells

1 reference

12 December 2020

Evidence from in vitro studies that tolerance to self antigens is MHC-restricted

1 reference

12 December 2020

Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells

1 reference

12 December 2020

Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation

1 reference

12 December 2020

Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens

1 reference

12 December 2020

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease

1 reference

12 December 2020

Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones

1 reference

12 December 2020

Allogeneic hemopoietic stem cell transplantation for patients with high risk acute lymphoblastic leukemia: favorable impact of chronic graft-versus-host disease on survival and relapse

1 reference

12 December 2020

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

12 December 2020

Self tolerance is H–2-restricted

1 reference

12 December 2020

Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

10.1046/J.1365-2249.2003.02055.X

Identifiers

DOI

1 reference

6 August 2017

0 references

1 reference

PubMed ID

12519379